Discover the SciOpen Platform and Achieve Your Research Goals with Ease.
Search articles, authors, keywords, DOl and etc.
Huang HY, Sharma HS, Chen L, et al. Neurorestoratology: new advances in clin-ical therapy. CNS Neurol Disord: Drug Targets. 2023;22(7):1031–1038. https://doi.org/10.2174/1871527321666220827093805.
Huang HY, Ramon-Cueto A, El Masri W, et al. Advances in Neurorestoratology-Current status and future developments. Int Rev Neurobiol. 2023;171:207–239. https://doi.org/10.1016/bs.irn.2023.04.003.
Huang HY, Sanberg PR, Moviglia GA, et al. Clinical results of neurorestorative cell therapies and therapeutic indications according to cellular bio-proprieties. Regen Ther. 2023;23:52–59. https://doi.org/10.1016/j.reth.2023.03.004.
Chen D, Huang HY, Saberi H, et al. Positive and negative cell therapy in ran-domized control trials for central nervous system diseases. Int Rev Neurobiol. 2023;171:241–254. https://doi.org/10.1016/bs.irn.2023.05.017.
Horwitz EM, le Blanc K, Dominici M, et al. Clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cyto-therapy. 2005;7(5):393–395. https://doi.org/10.1080/14653240500319234.
Kuroda Y, Kitada M, Wakao S, et al. Unique multipotent cells in adult human mesenchymal cell populations. Proc Natl Acad Sci U S A. 2010;107(19): 8639–8643. https://doi.org/10.1073/pnas.0911647107.
Lo Furno D, Mannino G, Giuffrida R, et al. Neural differentiation of human adipose-derived mesenchymal stem cells induced by glial cell conditioned me-dia. J Cell Physiol. 2018;233(10):7091–7100. https://doi.org/10.1002/jcp.26632.
Russo C, Mannino G, Patane M, et al. Ghrelin peptide improves glial condi-tioned medium effects on neuronal differentiation of human adipose mesen-chymal stem cells. Histochem Cell Biol. 2021;156(1):35–46. https://doi.org/10.1007/s00418-021-01980-3.
Shi JM, Yin M. Effect of Wnt/b-catenin signaling pathway in neural differentia-tion of human bone marrow mesenchymal stem cells. Chin J Reparative Reconstr Surg. 2023;37(10):1276–1283. https://doi.org/10.7507/1002-1892.202306017.
Jaiswal J, Dhayal M. Rapid neurogenic differentiation of human mesenchymal stem cells through electrochemical stimulation. Bioelectrochemistry. 2023;153:108468. https://doi.org/10.1016/j.bioelechem.2023.108468.
Thrivikraman G, Madras G, Basu B. Electrically driven intracellular and extra-cellular nanomanipulators evoke neurogenic/cardiomyogenic differentiation in human mesenchymal stem cells. Biomaterials. 2016;77:26–43. https://doi.org/10.1016/j.biomaterials.2015.10.078.
Wu H, Gordon JAR, Whitfield TW, et al. Chromatin dynamics regulate mesen-chymal stem cell lineage specification and differentiation to osteogenesis. Bio-chim Biophys Acta Gene Regul Mech. 2017;1860(4):438–449. https://doi.org/10.1016/j.bbagrm.2017.01.003.
Xie TQ, Huang QM, Huang QL, et al. Dysregulated lncRNAs regulate human um-bilical cord mesenchymal stem cell differentiation into insulin-producing cells by forming a regulatory network with mRNAs. Stem Cell Res Ther. 2024;15(1): 22. https://doi.org/10.1186/s13287-023-03572-5.
Dominici M, le Blanc K, Mueller I, et al. Minimal criteria for defining multipo-tent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317. https://doi.org/10.1080/14653240600855905.
Wakao S, Kuroda Y, Ogura F, et al. Regenerative effects of mesenchymal stem cells: contribution of muse cells, a novel pluripotent stem cell type that resides in mesenchymal cells. Cells. 2012;1(4):1045–1060. https://doi.org/10.3390/cells1041045.
Galipeau J, Krampera M, Barrett J, et al. International Society for Cellular Ther-apy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. 2016;18(2):151–159. https://doi.org/10.1016/j.jcyt.2015.11.008.
Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: international Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019–1024. https://doi.org/10.1016/j.jcyt.2019.08.002.
Viswanathan S, Ciccocioppo R, Galipeau J, et al. Consensus international council for commonality in blood banking automation-international society for cell & gene therapy statement on standard nomenclature abbreviations for the tissue of origin of mesenchymal stromal cells. Cytotherapy. 2021;23(12):1060–1063. https://doi.org/10.1016/j.jcyt.2021.04.009.
Ueda K, Sato Y, Shimizu S, et al. Systemic administration of clinical-grade mul-tilineage-differentiating stress-enduring cells ameliorates hypoxic-ischemic brain injury in neonatal rats. Sci Rep. 2023;13(1):14958. https://doi.org/10.1038/s41598-023-41026-3.
Xiang S, Gao W, Peng H, et al. Standards of clinical-grade mesenchymal stromal cell preparation and quality control (2020 China Version). J Neurorestoratol. 2020;8(4):197–216.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).